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Abstract
Dupilumab is a fully human antibody to interleukin-4 receptor α that improves the signs and 
symptoms of moderate to severe atopic dermatitis (AD). To determine the effects of dupilumab on 
Staphylococcus aureus colonization and microbial diversity on the skin, bacterial DNA was 
analyzed from swabs collected from lesional and nonlesional skin in a double-blind, placebo-
controlled study of 54 patients with moderate to severe AD randomized (1:1) and treated with 
either dupilumab (200 mg weekly) or placebo for 16 weeks. Microbial diversity and relative 
abundance of Staphylococcus were assessed by DNA sequencing of 16S ribosomal RNA, and 
absolute S. aureus abundance was measured by quantitative PCR. Before treatment, lesional skin 
had lower microbial diversity and higher overall abundance of S. aureus than nonlesional skin. 
During dupilumab treatment, microbial diversity increased and the abundance of S. aureus 
decreased. Pronounced changes were seen in nonlesional and lesional skin. Decreased S. aureus 
abundance during dupilumab treatment correlated with clinical improvement of AD and 
biomarkers of type 2 immunity. We conclude that clinical improvement of AD that is mediated by 
interleukin-4 receptor α inhibition and the subsequent suppression of type 2 inflammation is 
correlated with increased microbial diversity and reduced abundance of S. aureus.
INTRODUCTION
Atopic dermatitis (AD) is a complex disease characterized by chronic inflammation, barrier 
dysfunction, and microbial dysbiosis in the skin (Brunner et al., 2018; Brunner et al., 2017a; 
Werfel et al., 2016; Eichenfield et al., 2014; Cork et al., 2009; Bieber, 2008). Inflammation 
is driven predominantly by the type 2–T helper type 2 cytokine pathway (Brandt and 
Sivaprasad, 2011), in which the cytokines IL-4 and IL-13 play a major role (Brunner et al., 
2017a). Type 2–T helper type 2 cytokines can inhibit key components of skin barrier 
function, such as filaggrin and loricrin (Leung and Guttman-Yassky, 2014; Howell et al., 
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2009; Kim et al., 2008), alter skin lipid metabolism (Berdyshev et al., 2018), and inhibit 
antimicrobial peptide synthesis (Guttman-Yassky et al., 2008; Nomura et al., 2003; Kisich et 
al., 2007; Ong et al., 2002). These conditions facilitate binding and colonization by S. aureus 
(Cho et al., 2001), which is associated with increased inflammation and disease severity 
(Kobayashi et al., 2015; Bjerre et al., 2017; Hepburn et al., 2017; Gong et al., 2006; Leyden 
et al., 1974).
Dupilumab is a fully human VelocImmune-derived mAb (MacDonald et al., 2014; Murphy 
et al., 2014) that blocks the shared receptor subunit for IL-4 and IL-13, thus inhibiting 
signaling of IL-4 and IL-13 (Gandhi et al., 2015). It is approved for the treatment of adults 
with inadequately controlled moderate to severe AD and for asthma. In early phase and 
phase 3 clinical trials, dupilumab administered as monotherapy for up to 16 weeks, or with 
concomitant topical corticosteroids for 4 or 52 weeks, significantly improved signs and 
symptoms of AD in adults with moderate to severe AD, with an acceptable safety profile 
(Beck et al., 2014; Thaçi et al., 2016; Simpson et al., 2016; Blauvelt et al., 2017). Additional 
studies further characterized the impact of dupilumab-mediated IL-4Rα blockade on the 
molecular and cellular features of lesional and nonlesional skin in patients with moderate to 
severe AD (Hamilton et al., 2014; Guttman-Yassky et al., 2019). In a randomized 16-week, 
phase 2 trial (AD-1307 EXPLORE, registered with ClinicalTrials.gov NCT01979016 on 
November 1, 2013), dupilumab treatment significantly improved epidermal differentiation in 
lesional skin (Guttman-Yassky et al., 2019), suggesting normalization of skin barrier 
function. Here, we report additional findings from AD-1307 EXPLORE regarding microbial 
diversity, S. aureus abundance, and the impact of dupilumab treatment on these factors. The 
relation between S. aureus abundance and clinical and molecular markers of AD severity 
was also assessed.
RESULTS
Patients
A total of 54 patients were randomized to dupilumab 200 mg weekly (n = 27) or placebo (n 
= 27). Most patients completed the treatment phase: 26 of 27 (96.3%) in the dupilumab 
group and 25 of 27 (92.6%) in the placebo group. The number of patients completing both 
the treatment and follow-up phases (up to week 32) was 17 of 27 (63.0%) in the dupilumab 
group and 13 of 27 (48.1%) in the placebo group (additional information is available from 
Guttman-Yassky et al., 2019). Skin swabs were available from all 26 patients in the 
dupilumab group and from 27 patients in the placebo group at prespecified times.
Pretreatment characterization of lesional and nonlesional skin
At screening and baseline, lesional skin contained significantly higher quantities of bacteria 
than did nonlesional skin, based on absolute quantification of 16S ribosomal RNA (rRNA) 
using quantitative PCR (qPCR) (P < 0.05) (Figure 1a). Lesional skin also contained 
significantly higher quantities of S. aureus compared with nonlesional skin (P < 0.05) 
(Figure 1b). Shannon diversity results from 16S rRNA sequencing indicated that lesional 
skin had significantly lower microbial diversity than did nonlesional skin (Figure 1c). Alpha 
diversity scores for lesional and nonlesional skin were consistent in the two treatment 
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groups, confirming that both groups were similar in terms of bacterial diversity at baseline 
(Figure 1d) and were consistent in male and female patients at baseline (Figure 1e). Figure 
1f shows baseline Eczema Area and Severity Index (EASI) scores for male and female 
patients in each treatment group.
Relative microbial abundance
Figure 2 shows relative microbial abundance in lesional and nonlesional skin according to 
treatment group. The most abundant bacterial phyla were Firmicutes (mostly 
Staphylococcus), Actinobacteria (mostly Corynebacterium), and Proteobacteria (mostly 
Acinetobacter). The relative abundance of Staphylococcus decreased during dupilumab 
treatment in both lesional (P < 0.001) and nonlesional (P < 0.01) skin (Supplementary 
Figure S1), but the most pronounced reduction was seen in lesional skin samples 
(Supplementary Figure S2). This decrease in Staphylococcus abundance was observed as 
early as week 4 and was sustained until week 16. A relative abundance of bacterial taxa in 
lesional skin for individual dupilumab-treated patients over time is shown in Supplementary 
Figure S3.
Microbial diversity
Shannon microbial α-diversity over time is shown in Figures 3a–d. In the placebo group, 
microbial diversity was relatively consistent throughout the study for both lesional (Figure 
3a) and nonlesional skin (Figure 3c); the only time point at which α-diversity was 
significantly different from baseline was at week 32 for lesional skin (16 weeks after 
treatment). In contrast, in the dupilumab-treated group, α-diversity in lesional skin increased 
significantly from week 0 (includes screening and baseline) to week 4 and at all time points 
through week 16 (during treatment; P < 0.001). The effect was lost at week 32 (i.e., 18 
weeks after the last injection) (Figure 3b); similarly, in nonlesional skin, there was a 
significant increase (P < 0.05) in α-diversity from baseline at weeks 4, 8, 12, and 16 (Figure 
3d). Higher microbial α-diversity is associated with a lower relative abundance of 
Staphylococcus (P < 0.001, Spearman correlation; results not shown).
Figures 3e–g summarizes weighted UniFrac microbial β-diversity. In the dupilumab-treated 
group, samples taken from lesional skin during periods when no treatment was given (weeks 
0 and 32) cluster to the left of the plot and are highlighted in red, indicating low Shannon 
diversity and a return to pretreatment conditions (Figure 3e). During treatment, however, 
lesional skin samples from the dupilumab-treated group are shifted to the right and are 
highlighted in blue, indicating high Shannon diversity (Figure 3f). This shift in Shannon 
diversity can also be observed in plots color-coded according to treatment week; lesional 
skin samples from the dupilumab-treated group are shifted to the right after 4–16 weeks of 
dupilumab treatment compared with samples that received no dupilumab treatment (weeks 
−2, 0, or 32) which are clustered to the left (Supplementary Figure S4a). This distinction is 
not observed for nonlesional skin samples or placebo-treated skin samples (Supplementary 
Figures S4b–d). The principal coordinates analysis plot for all samples (placebo and 
dupilumab, lesional and nonlesional) at all time points showed a separation between lesional 
and nonlesional skin samples with significant separation between low and high Shannon 
diversity (P < 0.001) (Figure 3g).
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Absolute bacterial abundance over time
Absolute abundance of total bacteria and S. aureus in lesional skin samples is shown in 
Figure 4 and Supplementary Figure S1. Absolute abundance of total bacteria as measured by 
qPCR of 16S rRNA decreased during treatment with dupilumab (P < 0.01) (Supplementary 
Figure S1a) but not with placebo (Supplementary Figure S1b). The decreased abundance of 
total bacteria during dupilumab treatment was observed as early as week 4 and was 
sustained through week 32. Absolute abundance of S. aureus measured by qPCR also 
decreased during treatment with dupilumab (P < 0.001) (Figure 4a). This decrease was 
observed as early as week 4 (the first post-treatment time point tested) and continued 
through the end of treatment (week 16). By week 32 (16 weeks after treatment), S. aureus 
abundance had returned to baseline levels. In the placebo group, absolute abundance of S. 
aureus did not change consistently or significantly during dupilumab treatment (Figure 4b). 
Similar results were observed in nonlesional skin (Figures 4c–d); however, the only time 
point at which there was a significant decrease in absolute abundance of S. aureus in the 
placebo-treated group was at week 32, 16 weeks after treatment. Upon comparing the 
absolute abundance of S. aureus in lesional skin between the dupilumab and placebo 
treatment groups over time, the differences were statistically significant at weeks 4, 8, 12, 
and 16 (Supplementary Figure S5). Relative abundance of Staphylococcus also decreased 
with dupilumab treatment compared with placebo (Supplementary Figures S1c–f). There 
was a strong positive and significant correlation between relative abundance of 
Staphylococcus assessed using 16S rRNA gene sequencing and absolute S. aureus 
abundance determined using qPCR (P < 0.001) (Supplementary Figure S6), which 
demonstrated that although it is semi-quantitative, relative abundance of Staphylococcus is 
at least predictive for the abundance of S. aureus.
Staphylococcus aureus and clinical score
There was a significant correlation between both EASI and SCORAD scores and the relative 
abundance of Staphylococcus (P < 0.001, Spearman correlation) (Figure 5a and 
Supplementary Figure S7a) and absolute abundance of S. aureus (P < 0.001, Spearman 
correlation) (Figure 5b and Supplementary Figure S7b) in both lesional and nonlesional 
samples before treatment (weeks −2 and 0). The correlation between total bacterial 
abundance and SCORAD scores was significant (P < 0.001) in both lesional and nonlesional 
samples (Supplementary Figure S7c). In the dupilumab-treated group, samples clustered in 
the lower left corner of the plot at week 16, suggesting a reduction in both EASI scores and 
S. aureus abundance (Figure 5c), whereas samples from the placebo-treated group did not 
show this trend (Figure 5d). Furthermore, in lesional skin samples of the dupilumab-treated 
group, absolute abundance of S. aureus and EASI scores demonstrated similar dupilumab-
mediated reductions over time in both females and males (Supplementary Figure S8a–d), 
although the overall absolute abundance was higher in males than females.
Staphylococcus aureus and serum biomarkers
Pulmonary and activation-regulated chemokine (PARC/CCL18) and serum thymus and 
activation-regulated chemokine (TARC/CCL17), markers of type 2 inflammation, were 
shown to be associated with AD (Thijs et al., 2015; Pivarcsi et al., 2004). There was a 
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significant correlation between absolute abundance of S. aureus in both lesional and 
nonlesional samples before treatment (weeks −2 and 0) and serum concentrations of TARC 
(Figure 6a) and PARC (Figure 6b) in both lesional and nonlesional samples (P < 0.001, 
Spearman correlation). In the dupilumab-treated group, samples clustered in the lower left 
corner of the TARC plot at week 16, suggesting a reduction in both TARC score and S. 
aureus abundance with dupilumab treatment (Figure 6c), whereas samples from the placebo-
treated group did not show this trend (Figure 6d). A similar pattern was observed for PARC 
(Figure 6e–f).
DISCUSSION
Previous findings from this AD-1307 EXPLORE study of the impact of dupilumab 
treatment on skin in patients with moderate to severe AD indicated that dupilumab treatment 
reduces clinical signs and symptoms of AD and inflammatory cell infiltrates in lesional skin, 
inhibits type 2/T helper type 2 polarizing chemokines including PARC and TARC, and 
induces a progressive shift from a lesional to nonlesional molecular phenotype (Hamilton et 
al., 2014; Guttman-Yassky et al., 2019). This analysis of skin surface microbial DNA 
measurements confirmed that before treatment, the skin microbiome of AD is characterized 
by low microbial diversity and an increased abundance of S. aureus. Treatment with 
dupilumab for 16 weeks significantly changed the composition of the microbiome and 
increased microbial diversity while reducing the abundance of S. aureus. Increased diversity 
was observed as early as week 4 (the earliest time point tested); although this was more 
pronounced in lesional skin, clinically normal appearing (nonlesional) skin also showed a 
reduced amount of S. aureus. In contrast, no significant change in microbial diversity or S. 
aureus abundance was seen in the placebo-treated group. These findings suggest that 
targeting IL-4/IL-13 signaling via IL-4Rα blockade potentially enables the reduction of S. 
aureus colonization, a factor known to be associated with more severe AD in humans 
(Williams and Gallo, 2015) and with an AD-like phenotype in mice (Kobayashi et al., 2015; 
Nakatsuji et al., 2016).
Our characterization of the baseline skin microbiome in patients with AD is consistent with 
findings from other studies. A recent systematic review of studies assessing the skin 
microbiome found that AD is associated with frequent S. aureus colonization and low 
microbial diversity (Bjerre et al., 2017). Conventional culture-based studies showed that 
70% of lesional and 30–40% of nonlesional skin sites are predominantly colonized by S. 
aureus (Totté et al., 2016; Gong et al., 2006), which is associated with increased numbers of 
inflammatory cells in the skin (Boguniewicz and Leung, 2011) and more severe forms of 
AD (Bjerre et al., 2017). Previous studies also indicated that absolute levels of S. aureus 
correlate with EASI score and other markers of disease severity, including PARC and TARC 
(Thijs et al., 2015; Pivarcsi et al., 2004). Finally, Kong et al. (Kong et al., 2012) showed that 
AD flares are associated with increased S. aureus and decreased microbial diversity. 
Therefore, microbial diversity may be a useful biomarker in AD. However, AD remains a 
multifactorial disease, and the role of the skin microbiome in AD pathogenesis is still being 
studied (Bjerre et al., 2017; Williams and Gallo, 2015). Studies in animal models of AD 
investigating the response to topical S. aureus (Kobayashi et al., 2015; Nakatsuji et al., 2016) 
and observations that S. aureus colonization or microbiome dysbiosis can precede AD in 
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early childhood (Lebon et al., 2009; Meylan et al., 2017) support a role for the microbiome 
in exacerbation underlying inflammation that drives early AD pathogenesis.
Most currently available treatment options for AD do not address changes in the skin 
microbiome (Williams and Gallo, 2015; Hepburn et al., 2017). Topical antibiotic therapy 
may not reduce bacteria counts (Francis et al., 2017) and theoretically would not protect the 
normal skin microbiome (Williams and Gallo, 2015). Furthermore, frequent use of 
pharmaceutical antibiotics may promote antibiotic resistance (Hepburn et al., 2017; Salah 
and Faergemann, 2015). Several novel strategies are in development that target the skin 
microbiome, including the use of probiotics and transplantation of microbiota from healthy 
volunteers; further investigation of these strategies is needed (Nakatsuji et al., 2017; Myles 
et al., 2016). A promising treatment approach for AD will prevent dysbiosis by promoting or 
reestablishing a normal skin microbial flora (Williams and Gallo, 2015; Hepburn et al., 
2017).
Limitations of this exploratory analysis were the relatively small numbers of patients in both 
the dupilumab- and placebo-treated groups. However, efforts were made to minimize 
potential bias: skin swabs were collected from all patients participating in the clinical study 
(rather than being optional) and all samples were processed and evaluated in a blinded 
fashion. The use of a global EASI score compared with a target lesion score of the area of 
microbiome sampling is a potential methodological limitation of this study; however, the 
lesional area selected for skin swabbing was representative of overall disease severity as 
quantified by EASI score. Finally, analysis of DNA from skin surface microbial swabs does 
not assess bacterial survival or whether the microbes are metabolically active. Indeed, 
comparisons of S. aureus abundance measurements from lesional atopic to normal skin have 
shown that DNA assessments overestimate the capacity to culture S. aureus from healthy 
normal skin (Nakatsuji et al., 2017). These observations suggest that healthy skin can kill S. 
aureus more effectively than can skin from AD. Indeed, type 2 cytokines have been shown to 
suppress antimicrobial peptide production from keratinocytes (Ong et al., 2002). Future 
studies should examine the metabolic activity of bacteria and the host antimicrobial response 
of AD patients treated with dupilumab to assess the mechanism responsible for the 
improvement in the microbiome with treatment.
16S rRNA analysis of skin in adults with moderate to severe AD demonstrates decreased 
microbial α-diversity and a relative increase in the proportion of S. aureus. These changes 
are more pronounced in lesional than nonlesional areas. Dupilumab treatment reversed the 
AD-associated microbial (dysbiotic) signature for as long as patients were receiving 
treatment. Normalization of the microbial signature correlated with decreased concentration 
of serum biomarkers (TARC/PARC) and improvement in clinical signs and symptoms of 
AD. These results reveal strong links between the skin microbial community, type 2 
inflammation, and AD severity. To our knowledge, this characterization of the effect of a 
targeted treatment on the skin microbiome and type 2 inflammation has not been previously 
reported. An improvement of host defense against S. aureus colonization after inhibition of 
type 2 inflammation is consistent with the effects of type 2 cytokines to inhibit host 
antimicrobial peptide expression and impair barrier function (Guttman-Yassky et al., 2008; 
Nomura et al., 2003; Kisich et al., 2007; Ong et al., 2002). Future studies, including whole 
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metagenomic sequencing, will better define the role of S. aureus colonization in the 
initiation of AD pathogenesis and determine whether prolonged suppression of excessive 
type 2 immunity facilitates the reestablishment of a functional normobiotic shield in patients 
with AD.
MATERIALS AND METHODS
Trial design
AD-LIBERTY EXPLORE was a randomized, placebo-controlled, double-blind phase 2 trial 
(NCT01979016) conducted at five medical centers in the United States and Canada 
(Guttman-Yassky et al., 2019). Eligible patients were aged ≥18 years and had moderate to 
severe AD, defined as EASI ≥16; Investigator’s Global Assessment ≥3 (on the 0–4 
Investigator’s Global Assessment scale); body surface area ≥10%; AD present for ≥3 years; 
and inadequate response to topical medications within 6 months of screening. More detailed 
information on study patients is provided in Guttman-Yassky et al. (2019).
Fifty-four patients were randomized (1:1) to weekly subcutaneous injections of dupilumab 
or placebo. Patients received a loading dose of 400 mg (or placebo) followed by 200 mg (or 
placebo) every week for 16 weeks. Thereafter, patients entered a 16-week safety follow-up 
until week 32. The primary end point was percent change in EASI score from baseline to 
week 16 (continuous variable). Exploratory analyses included correlations between clinical 
severity (AD phenotype) and the host AD transcriptome, defined by lesional versus 
nonlesional skin gene expression differences, as well as changes from baseline to week 16 in 
S. aureus abundance and skin microbial diversity. This study was conducted in accordance 
with the Declaration of Helsinki International Conference on Harmonization, Good Clinical 
Practice guidelines, and applicable regulatory requirements. All study documents and 
procedures were approved by the appropriate institutional review boards and ethics 
committees at each study site; all participants provided written informed consent under 
institutional review board–approved protocols (Guttman-Yassky et al., 2019).
Pretreatment characterization of lesional and nonlesional skin
Abundance and diversity of bacterial colonization were characterized at weeks 0, 2, 4, 8, 12, 
16, and 32. Bacteria were collected from premeasured areas (10 × 10 cm) of lesional skin on 
the antecubital fossa and nonlesional skin of the upper arm at least 2 cm separated from the 
lesional site. Bacterial collection was performed by rubbing 50 strokes with a Catch-All 
nylon swab (Illumina, San Diego, CA) premoistened with Tris-EDTA buffer containing 
0.1% TritonX-100 and 0.05% Tween-20 (w/v) (Millepore-Sigma, St. Louis, MO). The swab 
was stored at −80°C until DNA extraction. Bacterial cells in the swab were lysed and total 
genomic DNA was purified. To characterize lesional and nonlesional skin before treatment, 
absolute quantification of bacterial abundance was performed using qPCR for skin samples 
collected at screening (week −2) and baseline (week 0). The abundance of S. aureus was 
performed using qPCR of the femA gene. Overall bacterial abundance was quantified using 
qPCR of the 16S rRNA. Shannon diversity results were also assessed based on 16S rRNA 
sequencing of skin samples collected at screening and baseline; diversity results were 
compared according to sex and treatment group.
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DNA extraction and 16S rRNA amplicon sequencing
16S rRNA sequencing was performed following the Earth Microbiome Project protocols 
(Gilbert et al., 2014; Caporaso et al., 2012). Briefly, DNA was extracted using the MO BIO 
PowerMag Soil DNA Isolation Kit (Qiagen, Carlsbad, CA) and the V4 region of the 16S 
rRNA gene was amplified using barcoded primers (Walters et al., 2016). The primers were 
shown to identify Staphylococcus genus sufficiently in mock communities (Gohl et al., 
2016). PCR was performed in triplicate for each sample, and V4 paired-end sequencing was 
performed using the Illumina MiSeq platform (San Diego, CA). Raw sequence reads were 
demultiplexed and quality controlled using the defaults, as provided by QIIME (San Diego, 
CA) (version 1.9.1) (Caporaso et al., 2010). The primary OTU table was generated using 
Qiita (San Diego, CA) (qiita.ucsd.edu), using Sort-MeRNA (Villeneuve d’Ascq, France) 
(Kopylova et al., 2012) and closed-reference OTU picking method against the GreenGenes 
database (San Francisco, CA version 13.8) (McDonald et al., 2012). OTU tables can be 
found in Qiita (qiita.ucsd.edu) as study ID 10403. Resulting OTU tables were then rarefied 
to 10,000 sequences/sample for downstream analyses.
Assessment of bacterial diversity
α- and β-diversity were assessed on the basis of 16S rRNA V4 amplicon DNA sequencing 
results from lesional and nonlesional skin samples collected at weeks −2, 0, 4, 8, 12, 16, and 
32. Microbial α-diversity was assessed using the Shannon index. Change in diversity from 
baseline was measured using the nonparametric Mann–Whitney U test. Microbial β-
diversity was measured using the weighted UniFrac distance metric and results are presented 
using multivariate analysis (principal coordinates analysis). Statistical significance was 
tested using nonparametric permutational multivariate analysis of variance using the Adonis 
function in R.
Quantitative PCR
Bacterial DNA was extracted from a 10 × 10-cm skin area by swabbing and eluted in 50 μl 
elution buffer. The abundance of total bacterial DNA in 1 μl elution was estimated by qPCR 
using a universal 16S rRNA primer set (1048-F: GTGSTGCAYGGYTGTCGTCA and 
1175-R: ACGTCRTCCMCACCTTCCTC) with Power SYBR green master mix (Applied 
Biosystems, Foster City, CA). The universal primer set covers 79% of Proteobacteria, 85% 
of Actinobacteria, 72% of Firmicutes, and 61% of Bacteroidetes (Horz et al., 2005). Because 
of a lack of standard bacteria that can be used as an external control of absolute 
quantification for universal 16S rRNA gene abundance, the abundance of 16S rRNA gene 
was calculated with a ∆Ct method and then normalized to the swabbed area. The abundance 
of S. aureus DNA was quantified using a species-specific primer set targeting femA (S. 
aureus femA-qPCR-2F: AACTGTTGGCCACTATGAGT; S. aureus femA-qPCR-2R: 
CCAG-CATTACCTGTAATCTCG) (Paule et al., 2004). The specificity of all primer pairs 
was confirmed by melting curve analysis and comparison with standard curves. To 
determine relative colony-forming unit of S. aureusespecific DNA, a standard curve was 
generated with genomic DNA extracted from standards derived from known amounts of 
colony-forming units of S. aureus (ATCC35556), and then the quantity was normalized to 
the swabbed area.
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Assessment of microbial abundance
Relative microbial abundance was assessed based on DNA sequencing of 16S rRNA isolated 
from lesional and nonlesional skin at weeks −2, 0, 4, 8, 12, 16, and 32; assessment of 
relative S. aureus abundance using 16S rRNA region V4 sequencing was semi-quantitative 
and is therefore described according to the genus level Staphylococcus. Change in the 
relative abundance of all bacteria was calculated. Absolute bacterial abundance over time 
was assessed using qPCR and primers for all bacteria. Absolute abundance of S. aureus was 
assessed as relative colony-forming units per square centimeter using qPCR and primers 
specific to S. aureus as described earlier. Statistical significance compared with baseline 
absolute abundance or between treatment groups was assessed using the nonparametric 
Mann–Whitney U test. No corrections on statistical tests were performed.
To assess bacterial abundance and microbial diversity, some samples were excluded due to 
rarefaction (i.e., sequence count was too low, not enough DNA was amplified). Also, in later 
weeks, not all patients provided a sample, with a decrease from week 4 to week 32.
Staphylococcus aureus and markers of disease severity
Correlation of EASI score with relative and absolute abundance of S. aureus was assessed. 
Relative abundance was measured using 16S rRNA amplicon sequencing, and absolute 
abundance was measured using qPCR and a primer specific to S. aureus. Correlation was 
also assessed between the absolute abundance of S. aureus and biomarkers of disease 
severity TARC and PARC (Ungar et al., 2017; Brunner et al., 2017b; Thijs et al., 2015; 
Pivarcsi et al., 2004). Serum TARC and PARC were measured using Quantikine ELISA kits 
(R&D Systems, Minneapolis, MN). Statistical significance was assessed using 
nonparametric Spearman rank correlation coefficient.
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AD atopic dermatitis
EASI Eczema Area and Severity Index
PARC pulmonary and activation-regulated chemokine
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REFERENCES
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in 
adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130–9. [PubMed: 
25006719] 
Berdyshev E, Goleva E, Bronova I, Dyjack N, Rios C, Jung J, et al. Lipid abnormalities in atopic skin 
are driven by type 2 cytokines. JCI Insight 2018;3.
Bieber T Atopic dermatitis. N Engl J Med 2008;358:1483–94. [PubMed: 18385500] 
Bjerre RD, Bandier J, Skov L, Engstrand L, Johansen JD. The role of the skin microbiome in atopic 
dermatitis: a systematic review. Br J Dermatol 2017;177:1272–8. [PubMed: 28207943] 
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term 
management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical 
corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-
controlled, phase 3 trial. Lancet 2017;389:2287–303. [PubMed: 28478972] 
Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune 
dysregulation. Immunol Rev 2011;24:233–46.
Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011;2. [PubMed: 
23504027] 
Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of AD and its reversibility with 
broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017a;139(Suppl. 4):S65–76. 
[PubMed: 28390479] 
Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in 
atopic dermatitis. Ann Allergy Asthma Immunol 2018;120:34–41. [PubMed: 29126710] 
Brunner PM, Suárez-Fariñas M, He H, Malik K, Wen HC, Gonzalez J, et al. The atopic dermatitis 
blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci 
Rep 2017b;7:8707. [PubMed: 28821884] 
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows 
analysis of high-throughput community sequencing data. Nat Methods 2010;7:335–6. [PubMed: 
20383131] 
Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-throughput 
microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012;6:1621–
4. [PubMed: 22402401] 
Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of 
Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest 
Dermatol 2001;116:658–63. [PubMed: 11348452] 
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al. Epidermal barrier 
dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892–908. [PubMed: 19494826] 
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of 
care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic 
dermatitis. J Am Acad Dermatol 2014;70:338–51. [PubMed: 24290431] 
Callewaert et al. Page 11
J Invest Dermatol. Author manuscript; available in PMC 2020 April 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Francis NA, Ridd MJ, Thomas-Jones E, Butler CC, Hood K, Shepherd V, et al. Oral and topical 
antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in 
ambulatory care. Ann Fam Med 2017;15:124–30. [PubMed: 28289111] 
Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal 
drivers in type 2 inflammation in disease. Nat Rev Drug Discov 2015;15:35–50. [PubMed: 
26471366] 
Gilbert JA, Jansson JK, Knight R. The Earth Microbiome Project: successes and aspirations. BMC 
Biol 2014;12:69. [PubMed: 25184604] 
Gohl DM, Vangay P, Garbe J, MacLean A, Hauge A, Becker A, et al. Systematic improvement of 
amplicon marker gene methods for increased accuracy in microbiome studies. Nat Biotechnol 
2016;34:942–9. [PubMed: 27454739] 
Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, et al. Skin colonization by Staphylococcus aureus in 
patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind 
multicentre randomized controlled trial. Br J Dermatol 2006;155:680–7. [PubMed: 16965415] 
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. 
Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis 
patients. J Allergy Clin Immunol 2019;143:155–72. [PubMed: 30194992] 
Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, et al. Low 
expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 
2008;181:7420–7. [PubMed: 18981165] 
Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves 
the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy 
Clin Immunol 2014;134: 1293–300. [PubMed: 25482871] 
Hepburn L, Hijnen DJ, Sellman BR, Mustelin T, Sleeman MA, May RD, et al. The complex biology 
and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. Br J 
Dermatol 2017;177:63–71. [PubMed: 27779765] 
Horz HP, Vianna ME, Gomes BP, Conrads G. Evaluation of universal probes and primer sets for 
assessing total bacterial load in clinical samples: general implications and practical use in 
endodontic antimicrobial therapy. J Clin Microbiol 2005;43:5332–7. [PubMed: 16208011] 
Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al. Cytokine modulation 
of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009;124(3 suppl 2):R7–12. 
[PubMed: 19720210] 
Kim BE, Leung DYM, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-
regulated by Th2 cytokines through STAT-6. Clin Immunol 2008;126:332–7. [PubMed: 18166499] 
Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY. The constitutive 
capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J 
Invest Dermatol 2007;127: 2368–80. [PubMed: 17460726] 
Kobayashi T, Glatz M, Horiuchi K, Kawasaki H, Akiyama H, Kaplan DH, et al. Dysbiosis and 
Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity 
2015;42:756–66. [PubMed: 25902485] 
Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin 
microbiome associated with disease flares and treatment in children with atopic dermatitis. 
Genome Res 2012;22:850–9. [PubMed: 22310478] 
Kopylova E, Noé L, Touzet H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in 
metatranscriptomic data. Bioinformatics 2012;28: 3211–7. [PubMed: 23071270] 
Lebon A, Labout JA, Verbrugh HA, Jaddoe VW, Hofman A, van Wamel WJ, et al. Role of 
Staphylococcus aureus nasal colonization in atopic dermatitis in infants: the Generation R Study. 
Arch Pediatr Adolesc Med 2009;163: 745–9. [PubMed: 19652107] 
Leung DYM, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting 
paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769–79. [PubMed: 
25282559] 
Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J 
Dermatol 1974;90:525–30. [PubMed: 4601016] 
Callewaert et al. Page 12
J Invest Dermatol. Author manuscript; available in PMC 2020 April 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MacDonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in 
situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 
2014;111:5147–52. [PubMed: 24706858] 
McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An improved 
Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and 
archaea. ISME J 2012;6:610–8. [PubMed: 22134646] 
Meylan P, Lang C, Mermoud S, Johannsen A, Norrenberg S, Hohl D, et al. Skin colonization by 
Staphylococcus aureus precedes the clinical diagnosis of atopic dermatitis in infancy. J Invest 
Dermatol 2017;137:2497–504. [PubMed: 28842320] 
Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase 
humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. 
Proc Natl Acad Sci U S A 2014;111:5153–8. [PubMed: 24706856] 
Myles IA, Williams KW, Reckhow JD, Jammeh ML, Pincus NB, Sastalla I, et al. Transplantation of 
human skin microbiota in models of atopic dermatitis. JCI Insight 2016;1:e86955.
Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human skin 
commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. 
Sci Transl Med 2017;9.
Nakatsuji T, Chen TH, Two AM, Chun KA, Narala S, Geha RS, et al. Staphylococcus aureus exploits 
epidermal barrier defects in atopic dermatitis to trigger cytokine expression. J Invest Dermatol 
2016;136: 2192–200. [PubMed: 27381887] 
Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic 
dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J 
Immunol 2003;171:3262–9. [PubMed: 12960356] 
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial 
peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151e60.
Paule SM, Pasquariello AC, Hacek DM, Fisher AG, Thomson RB Jr, Kaul KL, et al. Direct detection 
of Staphylococcus aureus from adult and neonate nasal swab specimens using real-time 
polymerase chain reaction. J Mol Diagn 2004;6:191–6. [PubMed: 15269294] 
Pivarcsi A, Gombert M, Dieu-Nosjean MC, Lauerma A, Kubitza R, Meller S, et al. CC chemokine 
ligand 18, a atopic dermatitis-associated and dendritic cell-derived chemokine, is regulated by 
staphylococcal products and allergen exposure. J Immunol 2004;173:5810–7. [PubMed: 
15494534] 
Salah LA, Faergemann J. A retrospective analysis of skin bacterial colonisation, susceptibility and 
resistance in atopic dermatitis and impetigo patients. Acta Derm Venereol 2015;95:532–5. 
[PubMed: 25367860] 
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of 
dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335–48. [PubMed: 
27690741] 
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab 
in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a 
randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387: 40–52. [PubMed: 
26454361] 
Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. 
Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin 
Immunol 2015;15:453–60. [PubMed: 26226355] 
Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence 
and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-
analysis. Br J Dermatol 2016;175:687–95. [PubMed: 26994362] 
Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An integrated model of 
atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol 
2017;137:603–13. [PubMed: 27825969] 
Walters W, Hyde ER, Berg-Lyons D, Ackermann G, Humphrey G, Parada A, et al. Improved bacterial 
16S rRNA gene (V4 and V4–5) and fungal internal transcribed spacer marker gene primers for 
microbial community surveys. mSystems 2016;1:e00009–15.
Callewaert et al. Page 13
J Invest Dermatol. Author manuscript; available in PMC 2020 April 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and 
molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 
2016;138:336–49. [PubMed: 27497276] 
Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma 
Rep 2015;15:65. [PubMed: 26404536] 
Callewaert et al. Page 14
J Invest Dermatol. Author manuscript; available in PMC 2020 April 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Pretreatment status of lesional and nonlesional skin.
(a) Absolute quantification of 16S rRNA using qPCR of skin samples at screening (week 
−2) and baseline (week 0). (b) Absolute quantification of Staphylococcus aureus using 
qPCR of skin samples at screening and baseline. (c) Shannon diversity results from 16S 
rRNA sequencing of skin samples at screening and baseline. (d) Shannon diversity results 
from 16S rRNA sequencing of skin samples at baseline (week 0) from the placebo and 
dupilumab-treated groups. (e) Shannon diversity results from 16S rRNA sequencing of skin 
samples at baseline of male and female patients. (f) EASI score at baseline for the placebo 
group and the dupilumab-treated group for male and female patients. Statistical differences 
between lesional and nonlesional skin, between treatment groups, and between males and 
females were assessed using the nonparametric Mann–Whitney U test, with Bonferroni 
correction for multiple comparison. EASI, Eczema Area and Severity Index; qPCR, 
quantitative PCR; rCFU, relative colony-forming units; rRNA, ribosomal RNA.
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Figure 2. Relative abundance of the most dominant phyla and genera over time in lesional and 
nonlesional skin according to treatment group.
The most abundant operational taxonomic units are presented. (a) Microbial variability over 
time of placebo group in lesional skin. (b) Microbial variability over time of dupilumab-
treated group in lesional skin. (c) Microbial variability over time of dupilumab-treated group 
in nonlesional skin. (d) Microbial variability over time of placebo group in nonlesional skin. 
During treatment (weeks 4–16), an overall decrease in relative abundance of Staphylococcus 
is noted mainly in the dupilumab-treated patients in lesional skin.
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Figure 3. Shannon microbial α-diversity and β-diversity.
(a–d) α-diversity: (a) Lesional skin, placebo group; (b) Lesional skin, dupilumab-treated 
group; (c) Nonlesional skin, placebo group; (d) Nonlesional skin, dupilumab-treated group. 
(e–g) β-diversity: PCoA plots showing Shannon diversity of skin samples; red indicates low 
diversity and blue indicates high diversity. (e) Large dots depict lesional skin samples from 
the dupilumab-treated group in periods without treatment (weeks −2, 0, and 32) and small 
dots represent other samples (nonlesional skin during periods of treatment), showing that 
without dupilumab treatment, samples are mainly located on the left side with a low 
Shannon diversity (red circle). (f) Large dots depict lesional skin samples from the 
dupilumab-treated group taken during the treatment period (weeks 4, 8, 12, and 16); small 
dots represent other samples (nonlesional skin, no treatment) showing that with dupilumab 
treatment, samples shift to the right with higher Shannon diversity (blue circle). (g) All 
samples (placebo and dupilumab, lesional and nonlesional skin) at all time points, indicating 
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a clear separation between lesional skin (left, low Shannon diversity [red]) and nonlesional 
skin (right, high Shannon diversity [blue]) and significant separation between low and high 
Shannon diversity (P < 0.001, Adonis test). Each dot represents an individual sample; the 
color of the dot reflects the bacterial Shannon diversity index on a continuous scale (red 
indicates low diversity and blue indicates high diversity). *P < 0.05, **P < 0.01, ***P < 
0.001; Mann–Whitney U test, with Bonferroni correction for multiple comparison. PCoA, 
Principal coordinates analysis.
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Figure 4. Absolute abundance Staphylococcus aureus over time.
(a) Lesional skin samples, placebo group. (b) Lesional skin, dupilumab-treated group. (c) 
Nonlesional skin samples, placebo group. (d) Nonlesional skin samples, dupilumab-treated 
group. *P < 0.05, **P < 0.01, ***P < 0.001; Mann–Whitney U test, with Bonferroni 
correction for multiple comparison. qPCR, quantitative PCR; rCFU, relative colony-forming 
units.
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Figure 5. Correlation of EASI score and relative and absolute abundance of Staphylococcus 
aureus.
At screening (week −2) and baseline (week 0): correlation of EASI score and (a) relative 
and (b) absolute abundance of S. aureus. Shaded areas around the regression line indicate 
confidence intervals. (c) Correlation of EASI scores and relative abundance of S. aureus at 
baseline and week 16 for both treatment groups and both lesional and nonlesional samples, 
with values from the placebo group at week 0 in yellow and week 16 in green. (d) Same as 
(c), with values from the dupilumab-treated group at week 0 in yellow and week 16 in green. 
Values for the same patient from weeks 0 and 16 are connected with a line. EASI, Eczema 
Area and Severity Index; qPCR, quantitative PCR; rCFU, relative colony-forming units; 
rRNA, ribosomal RNA.
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Figure 6. Correlation of absolute abundance of Staphylococcus aureus with biomarkers TARC 
and PARC.
(a) Correlation of TARC score and absolute abundance of S. aureus at screening (week −2) 
and baseline (week 0). (b) Correlation of PARC score and absolute abundance of S. aureus 
at screening (week −2) and baseline (week 0). Shaded areas around the regression line 
indicate confidence intervals. Correlation of TARC score and absolute abundance of S. 
aureus at baseline (yellow) and week 16 (green) in the (c) placebo group and the (d) 
dupilumab-treated group. Correlation of PARC score and absolute abundance of S. aureus at 
baseline (yellow) and week 16 (green) in the (e) placebo group and (f) dupilumab-treated 
group. Values for the same patient from weeks 0 and 16 are connected with a line. PARC, 
pulmonary and activation-regulated chemokine; qPCR, quantitative PCR; rCFU, relative 
colony-forming units; TARC, thymus and activation-regulated chemokine.
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